AbbVie (ABBV) is a publicly traded Healthcare sector company. As of May 20, 2026, ABBV trades at $212.09 with a market cap of $369.98B and a P/E ratio of 104.75. ABBV moved -0.58% today. Year to date, ABBV is -6.78%; over the trailing twelve months it is +15.10%. Its 52-week range spans $163.81 to $244.81. Analyst consensus is strong buy with an average price target of $254.11. Rallies surfaces ABBV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
DDW Reveals Risankizumab Lowers Steroid Use from 34% to 7% and Upadacitinib Reduces Hospitalizations 31%: AbbVie’s DDW presentations included a 52-week risankizumab study showing corticosteroid use fell from 34% to 7% and quality-of-life improvements in 77% of Crohn’s patients. Separate US claims data revealed a 14% two-year switch rate for risankizumab versus up to 36% for other biologics, and upadacitinib cut hospitalization odds by 31%.
| Metric | Value |
|---|---|
| Price | $212.09 |
| Market Cap | $369.98B |
| P/E Ratio | 104.75 |
| EPS | $2.03 |
| Dividend Yield | 1.73% |
| 52-Week High | $244.81 |
| 52-Week Low | $163.81 |
| Volume | 3.02M |
| Avg Volume | 0 |
| Revenue (TTM) | $62.82B |
| Net Income | $3.64B |
| Gross Margin | 70.68% |
20 analysts cover ABBV: 0 strong buy, 15 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $254.11.